D-Galactose is administered safely in diagnostic testing for both glycogen storage disease and cirrhotic liver disease (8) and as sonographic contrast agents, such as Levovist ® (Bayer). Galactose has also been successfully administered as a treatment in Fabry's disease. (9) In this case report, IV galactose infusions were administered at a dose of 1 g/kg every other day for 2 years during which time liver function tests remained normal. Possible associations between dairy intake and ovarian cancer has been investigated with inconclusive results. A 2006 pooled analysis of 12 cohort studies done by Harvard School of public health found no association of intake of dairy foods with ovarian cancer and a statistically insignificant increase in risk of ovarian cancer at intakes of lactose > 30 g/d. This study involved analyzing surveys of reported dairy intake, but did not account for the presence of other factors in milk, such as hormones, that could contribute to ovarian cancer risk (10). Another 2005 meta-analysis in the European Journal of Cancer Prevention found no association between milk/dairy products or galactose metabolism and ovarian cancer risk. (11) In addition to occurring naturally in milk, galactose has been approved by the FDA as a substance Generally Recognized as Safe (GRAS) as an ingredient in infant formula and other baby foods and pediatric nutrition supplements in the form of galacto-oligosaccharides (a compound made of 1 to 7 galactose molecules linked to a glucose molecule at the reducing end). (www.fda.gov/food/foodingredientspackaging/generallyrecognizedassafeGRAS/GRASListings/ucm1539 10.htm)